"#Cancer remains one of the main determinants of healthspan, not just lifespan. And while treatments have improved dramatically, the long-term consequences — #cardiotoxicity, #neuropathy, 2nd #cancers, #metabolic disruption — threaten the very longevity pts hope to gain." #CanSky #CancerBS
Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer
Therapeutic Advances in Drug Safety
@journals.sagepub.com
journals.sagepub.com/doi/10.1177/...
#womenshealth #cardiotoxicity #oncology #cancertreatment #openaccess
🆕Review article from Wouter C. Meijers, et al., "Forward and reverse cardio-oncology."
➡️ https://ow.ly/NL3Y50Y5GV6
#immunotherapy #cardio-oncology #cardiotoxicity
How can #CardiacMRI advance precision #oncology therapies? Join the #SiemensHealthineers Symposium at #SCMR2026 and find out! Listen as @marcofrancone shares his insights on using #MRI to monitor #cardiotoxicity - from targeted therapies to immunotherapies.
🤝 New partnership: AsedaSciences + Clyde Biosciences
We’re integrating CellOPTIQ® human-relevant cardiotoxicity data into the 3RnD® platform—enabling earlier, data-driven cardiac safety decisions within a modern NAM ecosystem.
Learn more: lnkd.in/eGJ9TRbd
@scicrunch.bsky.social #Cardiotoxicity
Planning to attend #SCMR2026 in #RiodeJaneiro? Join the #SiemensHealthineers Lunch Symposium on Friday, February 6, 2026! #lowfieldCMR #MAGNETOMFreeXL #cardiotoxicity
A novel cross-organ pathogenic communication between #BreastCancer and the heart via the exosomal miR-216a-5p-mediated ITCH/TXNIP/NLRP3 pathway, which drives cardiomyocyte #Pyroptosis, resulting in DOX-induced #Cardiotoxicity (DOXIC).
#STTT #OpenAccess: doi.org/10.1038/s413...
New study uses cross-modal integration of #metabolomics and cardiac functionality to capture dynamic metabotoxic effects of #doxorubicin in engineered heart tissues. #heartonchip #cardiotoxicity https://ow.ly/HfsS50XC6NI
ISSCR | The Gairdner Foundation | SickKids Foundation | Cell Press
What is the difference between forward & reverse #CardioOncology? 🎧 Dr. Carol Ann Remme interviews Dr. Rudolf de Boer about #cardiotoxicity due to anti-cancer therapies vs. #cancer discovered more often in patients with #cardiovascular disease 🎙️https://ow.ly/hB1g50Xnn3C
What is the difference between forward and reverse #CardioOncology? Listen to the latest episode of The Physiological Reviews Podcast discussing #Cancer, #CardiovascularDisease, #HeartFailure, and #Cardiotoxicity 🎧
https://ow.ly/isSC50XhR4y
🫀 Just published online in JPS❣️ (📖 Open Access!! 20 Oct 2025)
"Doxorubicin-induced sinus node dysfunction associated with mitochondria and nuclear impairment in a mouse model"
-- Kazuki Kobayashi et al.
🔗 doi.org/10.1016/j.jp...
#Cardiotoxicity #Mitochondria #Heart #NowOnline #JPhysiolSci.
Synapse: Your Connection to our MSK Authors
Meet: Richard M Steingart
Research Focus: Medicine; NE Emeritus
Cardiac safety of reduced cardiotoxicity surveillance during HER2-targeted therapy
synapse.mskcc.org/synapse/work...
#HER2Positive #BreastCancerResearch #Cardiotoxicity #CardioOncology
#Doxorubicin-treated #BreastCancer cells release #exosomal miR-216a-5p, which suppresses ITCH, stabilizes TXNIP, and activates the NLRP3 inflammasome to trigger #cardiomyocyte #pyroptosis. #cardiotoxicity @fudan-university.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
QT Interval and Hormone Receptors Predict Trastuzumab Cardiotoxicity
In 140 HER2‑positive breast cancer patients, 21.4% had LVEF decline; baseline QTc > 450 ms and low estrogen or progesterone receptors predicted cardiotoxicity risk. Read more: getnews.me/qt-interval-and-hormone-... #trastuzumab #cardiotoxicity
Calculate Corrected QT Interval (QTc) in 17 seconds with ONCOassist
#QTc #CorrectedQT #ONCOassist #OncologyTools #Cardiotoxicity #DigitalHealth #ClinicalCalculators #QTcBazett #QTInterval #MedTech
New review highlights challenges in modeling doxorubicin (DOX)-induced cardiotoxicity across animal models. Acute vs chronic models, species differences, and missing comorbidities limit translation to humans. Key for advancing personalized cardio-oncology therapies.
#Cardiotoxicity #CardioOncology
ROS, central to the cytotoxic effects of many #anticanceragents, disrupts redox homeostasis, contributing to inflammation, cellular dysfunction & long-term #adverseeffects like #cardiotoxicity, #neuropathy & #fibrosis. Chronic oxidative stress plays 🔑 role in modulating #drugresistance pathways,
🚨 Last Call for Submissions! 🚨
⏳ Deadline: August 2025 ⏳
📢 Don’t miss your chance to contribute to our Special Issue on Cardioprotection in Drug-Induced Cardiotoxicity.
🔗 Submit now: buff.ly/3uh2lPh
#Cardiotoxicity #Cardioprotection #Pharmacology
Proper fitness is a vital component in preventing #cardiotoxicity in #cancer survivors and promoting healthy living.
Join Dr Howden (🇦🇺 AUS) at #GCOS25 for an exciting session on how to integrate #CORE into treatment.
Join Us In Cape Town 🇿🇦: tinyurl.com/3kavnpxm
Serial Troponin Measurements May Help Predict Risk of Death After ICI Treatment.
#oncology #cardiotoxicity
academic.oup.com/oncolo/artic...
New research suggests that a healthy #GutMicrobiome before #chemotherapy could help protect #BreastCancerPatients against #HeartDamage, or #cardiotoxicity, as a result of #CancerTherapy.
#BreastCancer
New research suggests that a healthy #microbiome BEFORE #chemotherapy could help protect #breastcancer patients against #heartdamage, or #cardiotoxicity, as a result of #cancer #chemotherapy. #EuropeanSocietyofCardiology #ESC medicalxpress.com/news/2025-06...
There’s a disconnect in #CardioOnc: 80% of preclinical studies focus on #anthracyclines, yet <2% of clinical trials test them.
To prevent cancer Tx–related #cardiotoxicity, we need research that reflects today’s therapies www.jacc.org/doi/10.1016/...
#ESCardioOnco2025 #JACCCardioOnc #MedSky
Only a few months left to submit to our IJMS Special Issue on
Cardioprotection in Drug-Induced Cardiotoxicity.
Details: www.mdpi.com/journal/ijms...
Deadline: 20/Aug/2025
#Cardiotoxicity #CardioProtection #Pharmacology #CardioOncology #DrugSafety #HeartResearch #CancerTherapy
This article reviews the clinical manifestations and impact of #cardiotoxicity, explores the underlying mechanisms through animal studies, and proposes #ManagementStrategies from a multidisciplinary cardio-immuno-oncology perspective
#ICIs #medsky
#OpenAccess: buff.ly/LxUAD1H
💡 Cardioprotection & Drug-Induced Cardiotoxicity 💡
Have research on cardioprotective mechanisms, biomarkers, or interventions? 🫀💊 Submit to our Special Issue in IJMS!
📅 Deadline: August 2025
🔗 Details: buff.ly/3uh2lPh
#Cardiotoxicity #Cardioprotection #DrugSafety #Pharmacology #Toxicology
New in JMIR: AI-Assisted Hypothesis Generation to Address Challenges in #Cardiotoxicity #Research: Simulation #Study Using ChatGPT With GPT-4o
Advanced Imaging in Cardio-Oncology: Cardiac Magnetic Resonance for Cardiotoxicity Assessment by Federica Brilli, M.D.; Marco Francone, M.D., Ph.D.; et al. (Department of Biomedical Sciences, Humanitas University, Milan, Italy & IRCCS Humanitas Research Hospital, Milan, Italy) Advancements in cancer therapies have significantly improved survival rates, leading to a growing number of cancer survivors. However, this success also brings increased attention to therapy-related side effects—especially cardiovascular complications—which may manifest both acutely and chronically. In 2022, the International Cardio-Oncology Society (IC-OS) introduced a consensus definition for cancer therapy-related cardiac dysfunction (CTRCD), which includes conditions such as cardiomyopathy, heart failure (HF), myocarditis, vascular toxicity, hypertension (HTN), arrhythmias, and QT interval prolongation associated with anticancer treatments. This comprehensive framework aims to address long-standing issues of misclassification and misdiagnosis in the field. That same year, the European Society of Cardiology (ESC) published its first cardio-oncology guidelines, setting international standards for diagnosing and managing cancer therapy-related cardiovascular toxicity (CTR-CVT). This initiative involved collaboration with the European Hematology Association (EHA), the European Society for Radiotherapy and Oncology (ESTRO), and the International Cardio-Oncology Society, underscoring the need for a systematic approach to managing cardiovascular toxicities in cancer patients. The ESC guidelines emphasize early detection, risk assessment, and preventive measures to improve outcomes for this at-risk population. Learn how cardiac magnetic resonance (CMR) has become an essential tool in the early detection and management of chemotherapy-induced cardiotoxicity, offering significant financial, operational, and clinical advantages
#CMR is key in detecting chemo-induced #cardiotoxicity — offering clinical & economic value.
ESC & IC-OS guidelines push for early detection in #CardioOncology.
📖 Read more: www.magnetomworld.siemens-healthineers.com/clinical-cor...
#CardioSky #MRI #OncoSky @banksgaia.bsky.social #MagnetomWorld
New research finds #triazole #fungicides pose a significant risk of #cardiotoxicity with “concerns regarding their safety for human #health, especially in long-term #exposure." The authors' conclusion? #Prevention is the most effective approach. 💓 #ufs #unifesp #hearthealth ➡️ Blog: ow.ly/4pop50VoaaB
Don't miss our Israel chapter's webinar on how #cannabis can affect #cancer and #cardiotoxicity.
🎟️ Register today: docs.google.com/forms/d/1BZ9...
🇮🇱 Keep up with our Israel Chapter: ic-os.org/chapters/isr...
#cardioonc